TRβ-Selective Thyromimetic Esters for Tissue-Activated Remyelination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for selective thyromimetic compounds that can effectively treat neurodegenerative disorders such as multiple sclerosis and fibrotic diseases while avoiding the cardiotoxicity and bone demineralization associated with chronic hyperthyroidism, and for methods related to their use and preparation.
Innovation Solution
Development of thyromimetic compounds with specific structures that act as TRβ-selective agonists, including amide prodrugs and ester compounds, which are converted to active forms in tissues expressing high levels of FAAH or esterases, thereby enhancing tissue-specific delivery and minimizing systemic side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If thyroid hormone (TH) is used for remyelination therapy, then remyelination is achieved, but cardiotoxicity and bone demineralization occur due to chronic hyperthyroidism
Solution Approach 1:
The patent applies local quality by developing TRβ-selective agonists that preferentially activate thyroid hormone receptors in the brain and liver while minimizing activation in the heart and bone. This is achieved through molecular structure optimization to exploit the distinct ligand binding characteristics of TRβ versus TRα receptors, thereby achieving remyelination in the central nervous system without causing cardiotoxicity or bone demineralization associated with systemic hyperthyroidism.
Solution Approach 2:
The patent uses TRβ-selective agonists as intermediaries to indirectly achieve remyelination without directly administering thyroid hormone. These selective agonists act as mediators that trigger remyelination pathways through TRβ activation while avoiding the harmful effects of TH on cardiac and bone tissues, thus decoupling the therapeutic benefit from the adverse effects.
2Manufacturing precision
If TRβ-selective agonists are developed, then selectivity between TRα and TRβ is improved, but the high sequence homology of receptor subtypes makes this challenging
Solution Approach 1:
The patent applies asymmetry by introducing asymmetric structural modifications to the thyromimetic core structure to achieve differential binding affinity between TRα and TRβ receptors. Specifically, the patent employs asymmetric substitution patterns on the aromatic rings and chiral centers that exploit the asymmetric amino acid residue difference at position 385 (alanine in TRα vs. threonine in TRβ) within the ligand binding domain, thereby achieving TRβ selectivity despite overall high sequence homology.
Solution Approach 2:
The patent uses parameter changes by systematically varying molecular parameters such as substituent types, positions, and stereochemistry to optimize TRβ selectivity. The patent explores different substitution patterns (e.g., fluorine, chlorine, methyl groups at various positions), chain lengths, and functional groups to fine-tune the ligand-receptor interaction parameters, achieving the desired selectivity profile through iterative structural optimization.
3Ease of operation
If amide prodrugs and ester compounds are used, then tissue-specific delivery is enhanced, but conversion to active forms requires specific enzymatic conditions
Solution Approach 1:
The patent applies self-service by designing prodrugs that automatically convert to active forms within target tissues through endogenous enzymatic activity. The amide and ester prodrugs are structurally designed to be cleaved by tissue-specific enzymes (such as esterases or amidases) that are naturally present in the brain or other target organs, eliminating the need for external activation systems and enabling self-directed tissue-specific release of the active thyromimetic.
Solution Approach 2:
The patent uses enzymatic conversion as an intermediary step between prodrug administration and active drug action. The prodrug molecules serve as stable intermediaries that are transported to target tissues and then converted to active forms by local enzymes, thereby mediating the transition from systemic administration to localized therapeutic effect while protecting against premature activation or degradation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds achieve higher brain levels and targeted tissue activation, providing effective treatment for neurodegenerative disorders and fibrotic diseases with reduced systemic toxicity.
Implementation Method 1
converted to active forms in tissues expressing high levels of FAAH or esterases
Data Source
AI summary
Compounds are provided having the structure of Formula (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein R1, R2, X1, X2, Y1, and Y2 are as defined herein. Such compounds function as thyromimetics and have utility for treating diseases such as neurodegenerative disorders and fibrotic diseases. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation.